Skip to main content
. 2018 Apr 24;9(31):21674–21686. doi: 10.18632/oncotarget.24670

Figure 6. Pharmacodynamics (PD) study of new selumetinib-based combinations.

Figure 6

Normalized MAPK (MEK, p-MEK, ERK, p-ERK) (A) and Pi3K (AKT, p-AKT, S6, p-S6) (B) protein levels determined at the end of in vivo experiments. Western blot of MAPK (MEK, p-MEK, ERK, p-ERK) and Pi3K (AKT, p-AKT, S6, p-S6) protein levels (AKT, p-AKT, S6, p-S6) in the MP34 (C), MP46 (D), MP55 (E), MP77 (F), and MM26 (G) UM PDXs.